BioCryst Pharmaceuticals (BCRX) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

BioCryst Pharmaceuticals Revenue Highlights

Latest Revenue (Y)

$331.41M

Latest Revenue (Q)

$117.08M

Main Segment (Y)

Product

BioCryst Pharmaceuticals Revenue by Period

BioCryst Pharmaceuticals Revenue by Year

Date	Revenue	Change
2023-12-31	$331.41M	22.37%
2022-12-31	$270.83M	72.31%
2021-12-31	$157.17M	782.38%
2020-12-31	$17.81M	-63.53%
2019-12-31	$48.84M	136.45%
2018-12-31	$20.65M	-18.00%
2017-12-31	$25.19M	-4.43%
2016-12-31	$26.35M	-45.39%
2015-12-31	$48.26M	254.62%
2014-12-31	$13.61M	-21.48%
2013-12-31	$17.33M	-34.09%
2012-12-31	$26.29M	33.85%
2011-12-31	$19.64M	-69.07%
2010-12-31	$63.50M	-14.87%
2009-12-31	$74.59M	31.87%
2008-12-31	$56.56M	-20.60%
2007-12-31	$71.24M	1046.79%
2006-12-31	$6.21M	3990.38%
2005-12-31	$151.87K	-54.92%
2004-12-31	$336.90K	-79.38%
2003-12-31	$1.63M	-7.92%
2002-12-31	$1.77M	-84.10%
2001-12-31	$11.16M	236.52%
2000-12-31	$3.32M	32.62%
1999-12-31	$2.50M	-60.94%
1998-12-31	$6.40M	540.00%
1997-12-31	$1.00M	-62.96%
1996-12-31	$2.70M	1250.00%
1995-12-31	$200.00K	-71.43%
1994-12-31	$700.00K	-

BioCryst Pharmaceuticals generated $331.41M in revenue during NA 2023, up 22.37% compared to the previous quarter, and up 1604.67% compared to the same period a year ago.

BioCryst Pharmaceuticals Revenue by Quarter

Date	Revenue	Change
2024-09-30	$117.08M	7.09%
2024-06-30	$109.33M	17.86%
2024-03-31	$92.76M	-0.69%
2023-12-31	$93.40M	7.68%
2023-09-30	$86.74M	5.15%
2023-06-30	$82.49M	19.94%
2023-03-31	$68.78M	-13.54%
2022-12-31	$79.55M	4.90%
2022-09-30	$75.83M	15.71%
2022-06-30	$65.53M	31.27%
2022-03-31	$49.92M	5.86%
2021-12-31	$47.16M	15.04%
2021-09-30	$40.99M	-17.94%
2021-06-30	$49.96M	162.13%
2021-03-31	$19.06M	374.58%
2020-12-31	$4.02M	-34.19%
2020-09-30	$6.10M	112.54%
2020-06-30	$2.87M	-40.47%
2020-03-31	$4.82M	-87.86%
2019-12-31	$39.73M	2138.03%
2019-09-30	$1.77M	22.58%
2019-06-30	$1.45M	-75.40%
2019-03-31	$5.89M	115.72%
2018-12-31	$2.73M	87.69%
2018-09-30	$1.45M	-88.36%
2018-06-30	$12.49M	214.24%
2018-03-31	$3.98M	2.21%
2017-12-31	$3.89M	-55.59%
2017-09-30	$8.76M	182.67%
2017-06-30	$3.10M	-67.16%
2017-03-31	$9.44M	5.05%
2016-12-31	$8.98M	15.72%
2016-09-30	$7.76M	62.17%
2016-06-30	$4.79M	-0.68%
2016-03-31	$4.82M	4.74%
2015-12-31	$4.60M	-58.11%
2015-09-30	$10.99M	-57.48%
2015-06-30	$25.84M	278.58%
2015-03-31	$6.83M	25.34%
2014-12-31	$5.45M	68.19%
2014-09-30	$3.24M	120.87%
2014-06-30	$1.47M	-57.61%
2014-03-31	$3.46M	-67.28%
2013-12-31	$10.57M	342.32%
2013-09-30	$2.39M	190.99%
2013-06-30	$821.00K	-76.90%
2013-03-31	$3.55M	-13.34%
2012-12-31	$4.10M	-28.81%
2012-09-30	$5.76M	36.84%
2012-06-30	$4.21M	-65.55%
2012-03-31	$12.22M	133.94%
2011-12-31	$5.22M	-0.48%
2011-09-30	$5.25M	40.54%
2011-06-30	$3.73M	-31.28%
2011-03-31	$5.43M	-67.44%
2010-12-31	$16.69M	39.12%
2010-09-30	$12.00M	57.56%
2010-06-30	$7.62M	-70.79%
2010-03-31	$26.07M	-52.51%
2009-12-31	$54.90M	420.43%
2009-09-30	$10.55M	120.35%
2009-06-30	$4.79M	9.82%
2009-03-31	$4.36M	-87.27%
2008-12-31	$34.24M	284.98%
2008-09-30	$8.89M	234.49%
2008-06-30	$2.66M	-75.31%
2008-03-31	$10.77M	-61.78%
2007-12-31	$28.17M	-

BioCryst Pharmaceuticals generated $117.08M in revenue during Q3 2024, up 7.09% compared to the previous quarter, and up 141.94% compared to the same period a year ago.

BioCryst Pharmaceuticals Revenue Breakdown

BioCryst Pharmaceuticals Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Product	$324.70M	$267.71M	$17.53M	-	-
Collaborative And Other Research And Development	$6.72M	$214.00K	-	-	-
Milestone	-	-	-	-	-
Collaborative and Other Research and Development	-	-	$5.92M	$25.00M	-
Service	-	-	-	$757.00K	-
Royalty	-	-	-	-	$6.30M

BioCryst Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product (97.97%), and Collaborative And Other Research And Development (2.03%).

Quarterly Revenue by Product

Product/Service	Sep 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
Collaborative and Other Research and Development	$1.02M	$3.49M	$1.45M	$1.99M	$612.00K	$14.00K	$104.00K	$30.00K	$903.00K	$1.53M	$1.40M	$2.08M	$2.27M	$3.37M	$2.83M	$2.66M	$21.43M	$932.00K	-	-
Product	$116.07M	$89.27M	$239.41M	$85.29M	$78.06M	$75.21M	$64.89M	$605.00K	$2.48M	-	$218.00K	$15.52M	$335.00K	-	-	-	-	-	-	-
Royalty	-	-	-	-	-	-	$1.42M	$600.00K	$540.00K	$1.14M	$254.00K	$44.00K	$1.95M	$2.78M	$508.00K	-	-	-	-	-
Collaborative And Other Research And Development	-	-	-	-	-	-	$66.00K	-	-	-	-	-	-	-	-	-	-	-	-	-
Milestone Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

BioCryst Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Product (99.13%), and Collaborative and Other Research and Development (0.87%).

BioCryst Pharmaceuticals Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
APLS	Apellis Pharmaceuticals	$366.28M	$176.57M
BCRX	BioCryst Pharmaceuticals	$331.41M	$117.08M
AXSM	Axsome Therapeutics	$270.60M	$87.17M
BPMC	Blueprint Medicines	$249.38M	$128.18M
TGTX	TG Therapeutics	$233.66M	$83.88M
MCRB	Seres Therapeutics	$126.33M	-
PIRS	Pieris Pharmaceuticals	$42.81M	-
ATRA	Atara Biotherapeutics	$8.57M	$40.19M
KZR	Kezar Life Sciences	$7.00M	-
KRTX	Karuna Therapeutics	$654.00K	-
XFOR	X4 Pharmaceuticals	-	$560.00K
VKTX	Viking Therapeutics	-	-
PDSB	PDS Bio	-	-
DAWN	Day One Biopharmaceuticals	-	$20.07M
BIVI	BioVie	-	-
SAVA	Cassava Sciences	-	-
CGTX	Cognition Therapeutics	-	-
MDGL	Madrigal Pharmaceuticals	-	$62.17M
IMUX	Immunic	-	-
AVXL	Anavex Life Sciences	-	-
INMB	INmune Bio	$-155.00K	-

BCRX Revenue FAQ

What is BioCryst Pharmaceuticals’s yearly revenue?

BioCryst Pharmaceuticals's yearly revenue for 2023 was $331.41M, representing an increase of 22.37% compared to 2022. The company's yearly revenue for 2022 was $270.83M, representing an increase of 72.31% compared to 2021. BCRX's yearly revenue for 2021 was $157.17M, representing an increase of 782.38% compared to 2020.

What is BioCryst Pharmaceuticals’s quarterly revenue?

BioCryst Pharmaceuticals's quarterly revenue for Q3 2024 was $117.08M, a 7.09% increase from the previous quarter (Q2 2024), and a 34.98% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $109.33M, a 17.86% increase from the previous quarter (Q1 2024), and a 32.54% increase year-over-year (Q2 2023). BCRX's quarterly revenue for Q1 2024 was $92.76M, a -0.69% decrease from the previous quarter (Q4 2023), and a 34.87% increase year-over-year (Q1 2023).

What is BioCryst Pharmaceuticals’s revenue growth rate?

BioCryst Pharmaceuticals's revenue growth rate for the last 3 years (2021-2023) was 110.86%, and for the last 5 years (2019-2023) was 578.64%.

What are BioCryst Pharmaceuticals’s revenue streams?

BioCryst Pharmaceuticals's revenue streams in c 23 are Product, and Collaborative And Other Research And Development. Product generated $324.7M in revenue, accounting 97.97% of the company's total revenue, up 21.29% year-over-year. Collaborative And Other Research And Development generated $6.72M in revenue, accounting 2.03% of the company's total revenue, up 3038.32% year-over-year.

What is BioCryst Pharmaceuticals’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of BioCryst Pharmaceuticals was Product. This segment made a revenue of $324.7M, representing 97.97% of the company's total revenue.